

Our Ref: 496/2023
October 2023

Re: Your request made under the Freedom of Information Act 2000

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira - 15
- Adalimumab Biosimilar - 118
- Filgotinib - 0
- Golimumab - 3
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 227
- Mirikizumab - 0
- Ozanimod - 0
- Risankizumab - 0
- Tofacitinib - 0
- Upadacitinib - 2
- Ustekinumab - 109
- Vedolizumab - 83

Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.